Carregando...

Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis

Alemtuzumab is a selective humanized monoclonal antibody directed against the CD52 antigen, and has been found to be a powerful treatment for relapsing remitting multiple sclerosis. Alemtuzumab demonstrated high efficacy in several clinical studies. The risk of relapse and sustained accumulation of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ther Clin Risk Manag
Principais autores: Guarnera, Cristina, Bramanti, Placido, Mazzon, Emanuela
Formato: Artigo
Idioma:Inglês
Publicado em: Dove Medical Press 2017
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5522829/
https://ncbi.nlm.nih.gov/pubmed/28761351
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S134398
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!